Absci Corp SEC Filings

Absci (ABSI) reported an insider transaction on Form 4. The company’s CFO/CBO recorded a Code F transaction on 10/14/2025, reflecting 387 shares of common stock withheld by the issuer at $3.68 to satisfy taxes upon RSU vesting. Following this withholding, the reporting person directly owns 409,354 shares. The filing notes this was for tax withholding and not a discretionary trade.

Absci (ABSI) reported an insider Form 4 for its Chief Innovation Officer detailing tax withholding related to RSU vesting. On 10/14/2025, 3,092 shares of common stock were withheld under transaction code F at $3.68 to satisfy taxes, which the footnote clarifies was not a discretionary trade. Following this administrative transaction, the officer directly beneficially owns 324,172 shares.

Absci (ABSI) disclosed a Form 4 for a company officer (SVP, CAO). On 10/14/2025, 21,950 shares of common stock were withheld under code “F” to cover tax obligations upon the vesting of restricted stock units. The withholding price was $3.68 per share. After this transaction, the officer directly holds 161,283 shares. The filing states the withholding was for taxes related to RSU vesting and was not a discretionary trade.

Menelas N. Pangalos, a director of Absci Corp (ABSI), reported an open-market purchase of 95,785 shares of Absci common stock on 09/22/2025 at a price of $2.66 per share. After the transaction, Mr. Pangalos beneficially owned 113,960 shares. The filing states the purchase was made in accordance with the issuer's trading policies. The Form 4 was executed by Shelby Walker as attorney-in-fact on 09/22/2025.

Insider purchase by Absci Corp officer: Todd Bedrick, listed as SVP and CAO, reported an open-market purchase of 10,000 shares of Absci Corp (ABSI) on 09/22/2025 at a reported price of $2.70 per share. Following the transaction he beneficially owned 180,428 shares, held in a direct capacity. The Form 4 was signed by an attorney-in-fact on his behalf and notes the purchase was made in accordance with the issuer's trading policies.

Absci Corporation insider report: This Form 4 shows that Zachariah Jonasson, an officer serving as CFO/CBO, had 8,319 shares of Absci common stock withheld on 08/31/2025 to satisfy tax withholding related to the vesting and settlement of restricted stock units. The shares were withheld at a reported price of $2.39 per share. After the withholding, Mr. Jonasson is reported to beneficially own 409,741 shares of Absci common stock as a direct holder. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.

Absci Corporation filed Amendment No. 1 to its Current Report to correct a clerical error in the Original Form 8-K. The amendment fixes an incorrect reference to the press release date, changing it from June 12, 2025 to August 12, 2025, and corrects coding for Item 9.01. On August 12, 2025 the company furnished a press release announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and a corporate presentation with internal pipeline updates (Exhibit 99.2). The furnished materials are stated as "furnished" and not "filed."

Absci Corporation filed a preliminary Form S-3 shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units. The filing carries forward $75,175,613 of unsold securities from a prior registration and includes a sales agreement prospectus for up to $100,000,000 of common stock to be sold under a sales agreement with TD Securities (USA) LLC dated August 12, 2025. The company’s common stock trades on Nasdaq under ABSI and closed at $2.92 on August 7, 2025.

Absci describes its Integrated Drug Creation platform using generative AI for antibody design, reports over 25 partnered programs, and highlights internal programs ABS-101 (Phase 1 initiated May 2025; Phase 1b/2a anticipated H1 2026) and ABS-201 (IND filing targeted H1 2026; interim Phase 1 read-out targeted H2 2026). The prospectus is preliminary, references risk factors on page 10, notes the company is an emerging growth company and a smaller reporting company, and states proceeds will be used for general corporate purposes with management retaining broad discretion.

Absci Corporation reported reduced partner program revenue and higher research spending while advancing its AI-driven antibody pipeline. Revenue was $0.6 million for Q2 and $1.8 million for the six months ended June 30, 2025, down from $1.3 million and $2.2 million in the prior-year periods, respectively. Research and development expense rose 34% year-over-year to $36.8 million for the six months ended June 30, 2025, driven primarily by advancement of drug creation and external preclinical and clinical costs.

The company recorded a net loss of $30.6 million for the quarter and $56.9 million for the six months, with basic and diluted net loss per share of $0.45 for the six months. Cash, cash equivalents and short-term investments totaled $117.5 million at June 30, 2025. Subsequent equity raises after quarter-end generated net proceeds of approximately $60.6 million including an ATM sale and a public offering; Absci also completed a $20.0 million PIPE strategic collaboration with AMD in January 2025. The company initiated dosing in a Phase 1 study of ABS-101 in May 2025 and expects interim and IND-related milestones for ABS-101 and ABS-201 in 2025-2026. Partner revenue remained concentrated, with two partners contributing ~99% of Q2 partner revenue.